Literature DB >> 23703665

Advanced glycation endproducts induce fibrogenic activity in nonalcoholic steatohepatitis by modulating TNF-α-converting enzyme activity in mice.

Joy X Jiang1, Xiangling Chen, Hiroo Fukada, Nobuko Serizawa, Sridevi Devaraj, Natalie J Török.   

Abstract

UNLABELLED: Advanced glycation endproducts (AGEs) accumulate in patients with diabetes, yet the link between AGEs and inflammatory and fibrogenic activity in nonalcoholic steatohepatitis (NASH) has not been explored. Tumor necrosis factor alpha (TNF-α)-converting enzyme (TACE) is at the center of inflammatory processes. Because the main natural regulator of TACE activity is the tissue inhibitor of metalloproteinase 3 (Timp3), we hypothesized that AGEs induce TACE through nicotinamide adenine dinucleotide phosphate reduced oxidase 2 (NOX2); and the down-regulation of Sirtuin 1 (Sirt1)/Timp3 pathways mediate fibrogenic activity in NASH. The role of NOX2, Sirt1, Timp3, and TACE was evaluated in choline-deficient L-amino acid defined (CDAA) or Western diet (WD)-fed wild-type (WT) and NOX2(-/-) mice. To restore Timp3, mice were injected with adenovirus (Ad)-Timp3. Sirt1 and Timp3 expressions were studied in livers from NASH patients, and we found that their levels were significantly lower than in healthy controls. In WT mice on the CDAA or WD, Sirt1 and Timp3 expressions were lower, whereas production of reactive oxidative species and TACE activity significantly increased with an increase in active TNF-α production as well as induction of fibrogenic transcripts. Ad-Timp3 injection resulted in a significant decline in TACE activity, procollagen α1 (I), alpha smooth muscle actin (α-SMA) and transforming growth factor beta (TGF-β) expression. NOX2(-/-) mice on the CDAA or WD had no significant change in Sirt1, Timp3, and TACE activity or the fibrosis markers assessed. In vitro, AGE exposure decreased Sirt1 and Timp3 in hepatic stellate cells by a NOX2-dependent pathway, and TACE was induced after exposure to AGEs.
CONCLUSION: TACE activation is central to the pathogenesis of NASH and is mediated by AGEs through NOX2 induction and down-regulation of Sirt1/Timp3 pathways.
Copyright © 2013 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23703665      PMCID: PMC3897213          DOI: 10.1002/hep.26491

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  34 in total

Review 1.  Advanced glycosylation: chemistry, biology, and implications for diabetes and aging.

Authors:  R Bucala; A Cerami
Journal:  Adv Pharmacol       Date:  1992

2.  Systemic SIRT1 insufficiency results in disruption of energy homeostasis and steroid hormone metabolism upon high-fat-diet feeding.

Authors:  Aparna Purushotham; Qing Xu; Xiaoling Li
Journal:  FASEB J       Date:  2011-10-17       Impact factor: 5.191

3.  Purification of rat hepatic stellate cells by side scatter-activated cell sorting.

Authors:  A Geerts; T Niki; K Hellemans; D De Craemer; K Van Den Berg; J M Lazou; G Stange; M Van De Winkel; P De Bleser
Journal:  Hepatology       Date:  1998-02       Impact factor: 17.425

4.  Hepatic Sirt1 deficiency in mice impairs mTorc2/Akt signaling and results in hyperglycemia, oxidative damage, and insulin resistance.

Authors:  Rui-Hong Wang; Hyun-Seok Kim; Cuiying Xiao; Xiaoling Xu; Oksana Gavrilova; Chu-Xia Deng
Journal:  J Clin Invest       Date:  2011-10-03       Impact factor: 14.808

5.  Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1).

Authors:  K J Garton; P J Gough; C P Blobel; G Murphy; D R Greaves; P J Dempsey; E W Raines
Journal:  J Biol Chem       Date:  2001-08-08       Impact factor: 5.157

6.  Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE.

Authors:  M P Wautier; O Chappey; S Corda; D M Stern; A M Schmidt; J L Wautier
Journal:  Am J Physiol Endocrinol Metab       Date:  2001-05       Impact factor: 4.310

Review 7.  Advanced glycation end products and diabetic complications.

Authors:  Alan W Stitt; Alicia J Jenkins; Mark E Cooper
Journal:  Expert Opin Investig Drugs       Date:  2002-09       Impact factor: 6.206

8.  Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-alpha-dependent pathway.

Authors:  Vicki Thallas-Bonke; Suzanne R Thorpe; Melinda T Coughlan; Kei Fukami; Felicia Y T Yap; Karly C Sourris; Sally A Penfold; Leon A Bach; Mark E Cooper; Josephine M Forbes
Journal:  Diabetes       Date:  2007-10-24       Impact factor: 9.461

9.  Elevated levels of serum advanced glycation end products in patients with non-alcoholic steatohepatitis.

Authors:  Hideyuki Hyogo; Sho-ichi Yamagishi; Keiko Iwamoto; Koji Arihiro; Masayoshi Takeuchi; Takashi Sato; Hidenori Ochi; Michihiro Nonaka; Yoshitaka Nabeshima; Motoki Inoue; Tomokazu Ishitobi; Kazuaki Chayama; Susumu Tazuma
Journal:  J Gastroenterol Hepatol       Date:  2007-06-07       Impact factor: 4.029

10.  Mechanism of protein modification by glyoxal and glycolaldehyde, reactive intermediates of the Maillard reaction.

Authors:  M A Glomb; V M Monnier
Journal:  J Biol Chem       Date:  1995-04-28       Impact factor: 5.157

View more
  24 in total

1.  TNFα in liver fibrosis.

Authors:  Yoon Mee Yang; Ekihiro Seki
Journal:  Curr Pathobiol Rep       Date:  2015-09-30

2.  The NOX1 isoform of NADPH oxidase is involved in dysfunction of liver sinusoids in nonalcoholic fatty liver disease.

Authors:  Misaki Matsumoto; Jia Zhang; Xueqing Zhang; Junjie Liu; Joy X Jiang; Kanji Yamaguchi; Akiyuki Taruno; Masato Katsuyama; Kazumi Iwata; Masakazu Ibi; Wenhao Cui; Kuniharu Matsuno; Yoshinori Marunaka; Yoshito Itoh; Natalie J Torok; Chihiro Yabe-Nishimura
Journal:  Free Radic Biol Med       Date:  2017-12-20       Impact factor: 7.376

3.  NADPH Oxidases in Chronic Liver Diseases.

Authors:  Joy X Jiang; Natalie J Török
Journal:  Adv Hepatol       Date:  2014-11-30

4.  Isocaloric manipulation of macronutrients within a high-carbohydrate/moderate-fat diet induces unique effects on hepatic lipogenesis, steatosis and liver injury.

Authors:  Andrew A Pierce; Caroline C Duwaerts; Russell K Soon; Kevin Siao; James P Grenert; Mark Fitch; Marc K Hellerstein; Carine Beysen; Scott M Turner; Jacquelyn J Maher
Journal:  J Nutr Biochem       Date:  2015-11-17       Impact factor: 6.048

Review 5.  Updates on Dietary Models of Nonalcoholic Fatty Liver Disease: Current Studies and Insights.

Authors:  Kristen Stephenson; Lindsey Kennedy; Laura Hargrove; Jennifer Demieville; Joanne Thomson; Gianfranco Alpini; Heather Francis
Journal:  Gene Expr       Date:  2017-11-02

6.  Hepatocyte Nicotinamide Adenine Dinucleotide Phosphate Reduced Oxidase 4 Regulates Stress Signaling, Fibrosis, and Insulin Sensitivity During Development of Steatohepatitis in Mice.

Authors:  Ahmed Bettaieb; Joy X Jiang; Yu Sasaki; Tzu-I Chao; Zsofia Kiss; Xiangling Chen; Jijing Tian; Masato Katsuyama; Chihiro Yabe-Nishimura; Yannan Xi; Cedric Szyndralewiez; Kathrin Schröder; Ajay Shah; Ralph P Brandes; Fawaz G Haj; Natalie J Török
Journal:  Gastroenterology       Date:  2015-04-14       Impact factor: 22.682

7.  miR-200a controls hepatic stellate cell activation and fibrosis via SIRT1/Notch1 signal pathway.

Authors:  Jing-Jing Yang; Hui Tao; Li-Ping Liu; Wei Hu; Zi-Yu Deng; Jun Li
Journal:  Inflamm Res       Date:  2016-12-26       Impact factor: 4.575

Review 8.  Oxidative stress and hepatic Nox proteins in chronic hepatitis C and hepatocellular carcinoma.

Authors:  Jinah Choi; Nicole L B Corder; Bhargav Koduru; Yiyan Wang
Journal:  Free Radic Biol Med       Date:  2014-05-06       Impact factor: 7.376

Review 9.  Review article: emerging anti-fibrotic therapies in the treatment of non-alcoholic steatohepatitis.

Authors:  M Noureddin; Q M Anstee; R Loomba
Journal:  Aliment Pharmacol Ther       Date:  2016-04-08       Impact factor: 8.171

10.  Association between the soluble receptor for advanced glycation end products (sRAGE) and NAFLD in participants in the Atherosclerosis Risk in Communities Study.

Authors:  Marci Laudenslager; Mariana Lazo; Dan Wang; Elizabeth Selvin; Po-Hung Chen; James S Pankow; Jeanne M Clark
Journal:  Dig Liver Dis       Date:  2021-02-24       Impact factor: 5.165

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.